MRS 2957 triethylammonium salt
Cat. No. 4260
Chemical Name: P1-[5'(N4-Methoxycytidyl)]-P3-(5'-uri
Biological ActivityPotent P2Y6 agonist (EC50 = 12 nM). Displays 14- and 66-fold selectivity against P2Y2 and P2Y4 receptors respectively.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Maruoka et al (2010) Pyrimidine ribonucleotides with enhanced selectivity as P2Y6 receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate γ-ester modifications. J.Med.Chem. 53 4488. PMID: 20446735.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for MRS 2957 triethylammonium salt include:
Balasubramanian et al (2014) Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists. Nat Methods 9 e116203. PMID: 25549240.
Do you know of a great paper that uses MRS 2957 triethylammonium salt from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: MRS 2957 triethylammonium salt, supplier, MRS2957, triethylammonium, salt, potent, selective, purinergics, purines, purinoceptors, p2y6, agonists, Tocris Bioscience, Purinergic (P2Y) Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
December 13 - 15, 2016